The U.S. Food and Drug Administration (FDA) has launched an investigation into the potential risk of tumour formation associated with Novartis’ gene therapy, Zolgensma. This scrutiny arises after Novartis disclosed two specific cases where tumours in children appeared to be linked to the treatment, which is designed for patients under two years old suffering from spinal muscular atrophy. The FDA's inquiry focuses on the risk of neoplasia, including malignancies, in patients who have received this one-time gene therapy.

In total, Novartis has reported nine cases of tumours in patients treated with Zolgensma, prompting the FDA to take a closer look at the safety profile of the therapy. The investigation highlights the ongoing concerns regarding the long-term effects of gene therapies, particularly in vulnerable populations such as children. As the FDA delves deeper into these reports, the implications for Novartis and the future of Zolgensma could be significant, especially given the increasing reliance on gene therapies in treating rare genetic disorders.S1S2

The findings from this investigation could lead to new regulatory measures or changes in how gene therapies are administered and monitored. As the FDA continues its assessment, Novartis has committed to cooperating fully with the agency while ensuring that safety remains a top priority in their ongoing clinical evaluations. The outcome of this inquiry will be closely watched by healthcare providers and patients alike, as it may influence treatment protocols for spinal muscular atrophy and similar conditions moving forward.S1S2